U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H14N2O4
Molecular Weight 238.2403
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FELBAMATE

SMILES

c1ccc(cc1)C(COC(=N)O)COC(=N)O

InChI

InChIKey=WKGXYQFOCVYPAC-UHFFFAOYSA-N
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/felbamate.html and https://www.ncbi.nlm.nih.gov/pubmed/8383742

Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex. The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding. Felbamate should be used only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. Felbatol is the brand name used in the United States for felbamate.

CNS Activity

Originator

Approval Year

1993
136
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2575
Antagonist
2575
 0.52 mM [IC50]
Antagonist
2575
 2.02 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
FELBATOL

Approved Use

Not indicated as a first line antiepileptic treatment (see WARNINGS). Recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, Felbamate tablets can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

Launch Date

7.4381761E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.2 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9241102
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FELBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
49 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf027lbl.pdf
45 mg/kg 1 times / day steady-state, oral
dose: 45 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FELBAMATE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
526 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9241102
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FELBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
19.2 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9241102
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FELBAMATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf027lbl.pdf
45 mg/kg 1 times / day steady-state, oral
dose: 45 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
FELBAMATE plasma
Homo sapiens
population: UNKNOWN
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
n = 5
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years (range: 18-45 years)
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Other AEs: Headache, Nausea...
Other AEs:
Headache (1 patient)
Nausea (5 patients)
Anorexia (3 patients)
Dyspepsia (1 patient)
Insomnia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Other AEs: Fatigue, Weight decrease...
Other AEs:
Fatigue (6.9%)
Weight decrease (3.4%)
Face edema (3.4%)
Insomnia (8.6%)
Headache (6.9%)
Anxiety (5.2%)
Acne (3.4%)
Rash (3.4%)
Dyspepsia (8.6%)
Vomiting (8.6%)
Constipation (6.9%)
Diarrhea (5.2%)
SGPT increased (5.2%)
Hypophosphatemia (3.4%)
Upper respiratory tract infection (8.6%)
Rhinitis (6.9%)
Diplopia (3.4%)
Otitis media (3.4%)
Bleeding intermenstrual (3.4%)
Urinary tract infection (3.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Dyspepsia 1 patient
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
n = 5
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years (range: 18-45 years)
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Headache 1 patient
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
n = 5
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years (range: 18-45 years)
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Insomnia 1 patient
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
n = 5
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years (range: 18-45 years)
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Anorexia 3 patients
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
n = 5
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years (range: 18-45 years)
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Nausea 5 patients
1200 mg 3 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 3 times / day
Route: oral
Route: steady
Dose: 1200 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
unhealthy, 30 years (range: 18-45 years)
n = 5
Health Status: unhealthy
Condition: epilepsy
Age Group: 30 years (range: 18-45 years)
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9579889/
Acne 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Bleeding intermenstrual 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Diplopia 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Face edema 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Hypophosphatemia 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Otitis media 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Rash 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Urinary tract infection 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Weight decrease 3.4%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Anxiety 5.2%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Diarrhea 5.2%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
SGPT increased 5.2%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Constipation 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Fatigue 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Headache 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Rhinitis 6.9%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Dyspepsia 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Insomnia 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Upper respiratory tract infection 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Vomiting 8.6%
1200 mg 3 times / day multiple, oral
Recommended
Dose: 1200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
unhealthy, adult
n = 58
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 58
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1601

inducer
707
inhibitor
1604
inhibitor
1702

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
1325

CYP1A2
1383

CYP2A6
627

CYP2E1
790
CYP2E1
606

P-gp
1400
CYP2C19
269
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1772
 likely
yes (co-administration study)
Comment: Felbamate reduced mean gestodene AUCO-24h by -42% compared with baseline, while a minor decrease (-13%), which was not assessed to be clinically relevant, was observed in ethinyl estradiol AUCO-24h
Page: 7.0
CYP2A6
659
 no
CYP2C9
1648
 no
CYP2D6
1738
 no
CYP2E1
871
 slight
CYP1A2
1532
 yes [Inhibition 1 uM]
CYP2C19
1392
 yes [Ki 225 uM]
weak (co-administration study)
Comment: AUCtao of phenytoin (substrate) increased by 30% when given Felbamate (1200 mg/day)
Page: 6.0
CYP2C19
1392
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
1400
 likely
CYP2E1
606
 yes
CYP3A4
1601
 yes
weak (co-administration study)
Comment: Carbamazepine and phenytoin increased felbamate apparent clearance by 32 to 38% relative to monotherapy
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4995
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4995
ChemicalBook
CB6689427
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6689427
MolPort
MolPort-003-666-873
https://www.molport.com/shop/molecule-link/MolPort-003-666-873
Selleck Chemicals
Felbamate
http://www.selleckchem.com/products/Felbamate.html
ZINC
ZINC000001530803
http://zinc15.docking.org/substances/ZINC000001530803
eMolecules
538231
https://www.emolecules.com/cgi-bin/more?vid=538231
PubMed

PubMed

TitleDatePubMed
Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice.
1992 Mar
Felbamate, a novel antiepileptic agent, does not affect cognition in rodents.
1994 Jun
Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain.
1999 Apr
Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
1999 May
Felbamate in experimental model of status epilepticus.
2000 Feb
A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate.
2000 Jul
[New antiepileptic drugs in childhood epilepsies: indications and limits].
2001
Second generation anticonvulsant medications: their use in children.
2001 Apr
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
[Antiepileptic drugs and neuropathic pain].
2001 Feb 16-28
The role of new antiepileptic drugs.
2001 Jul
Monotherapy trials: presurgical studies.
2001 May
The long-term use of felbamate in children with severe refractory epilepsy.
2001 Nov
The NMDA receptor complex: a promising target for novel antiepileptic strategies.
2001 Sep
Anticonvulsants: aspects of their mechanisms of action.
2002
New antiepileptic drugs: review on drug interactions.
2002 Feb
Marketed new antiepileptic drugs: are they better than old-generation agents?
2002 Feb
Interaction between human serum albumin and the felbamate metabolites 4-Hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal.
2002 Jun
Polytherapy in epilepsy: the experimental evidence.
2002 Nov
Drug treatment of epilepsy in elderly people: focus on valproic Acid.
2003
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
2003 Dec
Influence of some convulsant agents on the protective activity of a novel antiepileptic drug, felbamate, against maximal electroshock in mice.
2003 Jul-Aug
Therapeutic drug monitoring of the newer antiepileptic drugs.
2003 Jun
Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice.
2003 Mar 28
Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions.
2004 Dec
Behavioural effects of the newer antiepileptic drugs: an update.
2004 Jan
New antiepileptic agents.
2004 Jan-Feb
Influence of felbamate on selected central effects of ethanol in experimental animals.
2004 May-Jun
Is there any future for felbamate treatment?
2004 May-Jun
Significance of MDR1 and multiple drug resistance in refractory human epileptic brain.
2004 Oct 9
Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis.
2005 Mar
Patents

Patents

JP2007512339A
40
JP2007525670A
139
JP4813359B2
2
JPH07309860A
1
JPH0769949A
1

Sample Use Guides

In Vivo Use Guide
Adjunctive therapy: 1200 mg/day in 3-4 divided doses. The daily dose can be increased in 1200 mg increments each week as tolerated to response. Maximum daily dose: 3600 mg. Monotherapy: 1200 mg/day in 3-4 divided doses. Increase the daily dose in 600 mg increments every two weeks as tolerated to response.
Route of Administration: Oral
In Vitro Use Guide
At concentrations of 30 to 100 nM, Felbamate produced a significant inhibition of high-voltage-activated Ca++ currents (-6/-15%). At saturating concentrations (1-3 uM), Felbamate-mediated inhibition averaged 44% in rat cortical and neostriatal neurons.
Name Type Language
FELBAMATE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ADD-03055
Code English
W-554
Code English
FELBAMATE [ORANGE BOOK]
Common Name English
FELBAMATE [WHO-DD]
Common Name English
FELBAMATE [USP MONOGRAPH]
Common Name English
CARBAMIC ACID 2-PHENYLTRIMETHYLENE ESTER
Common Name English
FELBAMATE [MI]
Common Name English
FELBAMATE [USP-RS]
Common Name English
2-PHENYL-1,3-PROPANEDIOL 1,3-DICARBAMATE
Common Name English
FELBAMATE [INN]
Common Name English
1,3-PROPANEDIOL, 2-PHENYL-, DICARBAMATE
Systematic Name English
FELBATOL
Brand Name English
FELBAMATE [VANDF]
Common Name English
FELBAMATE [USAN]
Common Name English
FELBAMATE [MART.]
Common Name English
TALOXA
Brand Name English
FELBAMATE [HSDB]
Common Name English
NSC-759866
Code English
Classification Tree Code System Code
LIVERTOX 401
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
NCI_THESAURUS C264
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
NDF-RT N0000008486
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
NDF-RT N0000175753
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
FDA ORPHAN DRUG 33488
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
WHO-ATC N03AX10
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
WHO-VATC QN03AX10
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
Code System Code Type Description
RXCUI
24812
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY RxNorm
MESH
C047360
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
NCI_THESAURUS
C47530
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
EPA CompTox
25451-15-4
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
IUPHAR
5473
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
EVMPD
SUB07526MIG
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
CAS
25451-15-4
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
HSDB
7525
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
FDA UNII
X72RBB02N8
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
WIKIPEDIA
FELBAMATE
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
DRUG BANK
DB00949
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
MERCK INDEX
M5254
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY Merck Index
LACTMED
Felbamate
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
PUBCHEM
3331
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
INN
5686
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
DRUG CENTRAL
1140
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
USP_CATALOG
1269312
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
247-001-4
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL1094
Created by admin on Fri Jun 25 22:05:41 UTC 2021 , Edited by admin on Fri Jun 25 22:05:41 UTC 2021
PRIMARY
ACTIVE MOIETY
Structure of FELBAMATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966